Overestimation of anticoagulant benefit in patients with atrial fibrillation and low life expectancy: evidence from 12 randomized trials

Sachin J. Shah, MD, MPH (1); Carl van Walraven, MD, MSc (2); Sun Young Jeon, PhD (3); W. John Boscardin, PhD (3, 4); FD Richard Hobbs, FMedSci (5), Stuart Connolly, MD (6); Michael Ezekowitz MB, ChB, DPhil (7); Kenneth E. Covinsky, MD, MPH (3); Margaret Fang, MD, MPH (3), Daniel E. Singer, MD (1)

(1) Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
(2) Departments of Medicine and Epidemiology & Community Medicine, University of Ottawa, Ottawa ON, CA
(3) Department of Medicine, University of California San Francisco, San Francisco, CA, USA
(4) Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, USA
(5) Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford UK
(6) Population Health Research Institute, McMaster University, Hamilton, ON, Canada
(7) Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA and Cardiovascular Medicine, Lankenau Institute for Medical Research, Wynnewood, PA, USA

Corresponding Author

Sachin J. Shah, MD, MPH

100 Cambridge Street, Suite 1600

Boston, MA 02114

sshah@mgh.harvard.edu

415-862-8616

Manuscript: 3113 words

Abstract: 266 words

Abstract

Objectives: Compare anticoagulant benefit for patients with atrial fibrillation estimated with the

CHA_2DS_2-VASc model vs. a Competing Risk Model that accounts for the competing risk of

death and does not assume a consistent growth in treatment benefit over time.

Design: Secondary analysis of randomized controlled trials (RCTs).

Setting: 12 RCTs randomizing patients with atrial fibrillation to oral anticoagulants or either

placebo or antiplatelets.

Participants: 7933 adults with non-valvular atrial fibrillation.

Exposure: Predicted anticoagulant absolute risk reduction (ARR) by guideline-endorsed model

(CHA_2DS_2-VASc) vs. a Competing Risk Model that uses the same inputs as CHA2DS2-VASc

but accounts for the competing risk of death and allows for non-linear growth in benefit over

time.

Main outcome measures: Ischemic stroke or systemic embolism

Results: 7933 participants had a median life expectancy of 8 years (IQR 6, 12), determined by

comorbidity-adjusted life tables. 43% were randomized to oral anticoagulation (median age 73

years, 36% women). The guideline-endorsed CHA_2DS_2-VASc model estimated a larger ARR

than the Competing Risk Model (median ARR at 3 years, 6.9% vs. 5.2%). ARR differences

varied by life expectancies: for those with life expectancies in the highest decile, 3-year ARR

difference (CHA_2DS_2-VASc model – Competing Risk Model 3-year risk) was -1.2% (42%

relative underestimation); for those with life expectancies in the lowest decile, 3-year ARR

difference was 5.9% (91% relative overestimation).

Conclusions: Anticoagulants effectively reduced stroke risk, but their benefits were

misestimated with CHA_2DS_2-VASc, which does not account for the competing risk of death nor

decelerating treatment benefit over time. Overestimation was most pronounced in patients with

the lowest life expectancy and when benefit was estimated over a multi-year horizon.

Introduction

Anticoagulants are the mainstay of preventative therapy for millions of older adults with atrial fibrillation. While anticoagulants reduce the risk of ischemic stroke and systemic embolism, they also increase the risk of bleeding. To help patients and clinicians weigh the risks and benefits of treatment, clinical guidelines and decision support tools endorse using the CHA_2DS_2-VASc score to estimate a patient's annual risk of ischemic stroke or systemic embolism without treatment.[1–5] The ACC/AHA/HRS consensus guidelines recommend that this baseline risk be used to estimate a patient's expected absolute risk reduction by applying the relative risk reduction from a meta-analysis of randomized trials.[1,6] Guidelines recommend anticoagulant therapy when the absolute risk reduction exceeds a threshold. The premise is that treatment benefits outweigh risks when an individual's estimated event risk exceeds this threshold.

While transparent, this approach makes two assumptions that can affect the accuracy of expected benefit. First, this approach does not account for the competing risk of death. A competing risk is an alternative outcome that occurs before, and necessarily precludes, the event of interest (e.g., cancer death before stroke from atrial fibrillation), thus limiting the absolute benefit achievable by anticoagulant treatment.[7–11] Competing risks are germane to anticoagulant use in atrial fibrillation because 80% of older adults with atrial fibrillation have geriatric syndromes (e.g., falls, activities of daily living impairments), which are associated with limited life expectancy.[12,13] Second, this approach assumes that the therapeutic benefit continues to increase at a constant rate over time—that is, the risk of stroke over two years is twice the one-year risk and thus the absolute risk reduction over two years is twice the one-year absolute risk reduction. Both issues are readily addressed by estimating benefit using a competing risk model; however, it is unknown if doing so will materially affect absolute risk reduction estimates attributable to anticoagulants.

We used patient-level data from 12 randomized trials of anticoagulants for atrial

fibrillation to determine if a competing risk model affects the measurement of absolute stroke

risk reduction. First, we compared the guideline-endorsed approach to measuring absolute risk

reduction (i.e., CHA_2DS_2-VASc score) to a competing risk model (i.e., Fine-Gray model[14]), using

the same covariates as the CHA_2DS_2-VASc score to estimate risk reduction. Second, we

determined if differences in expected stroke risk reduction between the guideline-endorse

CHA_2DS_2-VASc approach and a competing risk model varied by life expectancy.

Methods

Study design and participants

We used patient-level data from the Atrial Fibrillation Investigators (AFI) database to

address the study objectives. In brief, the AFI database contains patient-level data from 12

published clinical trials where patients were randomized to full-dose oral anticoagulant (OAC),

antiplatelets, or placebo. Trials include Atrial Fibrillation, Aspirin, and Anticoagulation Study 1

(AFASAK-1),[15] AFASAK-2,[16] Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF),[17]

Birmingham Atrial Fibrillation Treatment of the Aged Study (BAFTA),[18] Canadian Atrial

Fibrillation Anticoagulation (CAFA),[19] European Atrial Fibrillation Trial (EAFT),[20] Primary

Prevention of Arterial Thromboembolism in Atrial Fibrillation (PAATAF),[21] National Study for

Prevention of Embolism in Atrial Fibrillation (NASPEAF),[22] the Stroke Prevention in Atrial

Fibrillation 1 (SPAF-1),[23] SPAF-2,[24] SPAF-3,[25] and Stroke Prevention in Non-rheumatic Atrial

Fibrillation (SPINAF).[26] We did not include patients with mitral stenosis and patients in SPAF-1,

EAFT, PATAF, and SPAF-3 who were deemed ineligible to receive anticoagulants (trial details

in **Appendix 1** and **Appendix 2**).

Participant characteristics

Research coordinators and physicians collected patient characteristics before therapy

initiation. While specific features varied from study to study, common elements included a

history of stroke or transient ischemic attack, hypertension or systolic blood pressure ≥160

mmHg or use of antihypertensives, diabetes, angina, myocardial infarction, peripheral vascular

disease, smoking, and congestive heart failure, and body mass index. History of myocardial

infarction was not collected in NASPEAF and peripheral vascular disease was not collected in

AFASAK1, BAATAF, or BAFTA. Because history of myocardial infarction and peripheral

vascular disease were missing for all participants in specific trials, we assumed they were

missing at random and imputed them in 20 datasets using chained equations.[27] We excluded

<1% of participants who were missing data otherwise collected in a given trial (**Appendix 3**).

Treatment exposure

We examined all patients based on their treatment allocation (i.e., intention to treat).

Because studies have shown that antiplatelet and low-dose warfarin are ineffective

thromboprophylaxis in AF,[6] we categorized all trial participants as being randomized to full-dose

anticoagulants or control. Patients randomized to placebo, antiplatelets, low-dose warfarin, or

low-dose warfarin with aspirin were considered controls. AFASAK2, PAATAF, and SPAF3 used

low-dose warfarin and reported a mean international normalized ratio (INR) of < 1.5 supporting

their categorization as a control. While NASPEAF also had a low-dose anticoagulant arm, the

mean INR was 2.0; therefore, we excluded participants randomized to the NASPEAF low-dose

anticoagulant arm.

Outcome ascertainment

The primary outcome was ischemic stroke or systemic embolism. We detail outcome

definitions by trial in **Appendix 4**. In general, trials defined ischemic stroke as a focal

neurological deficit lasting >24 hours. All trials except AFASAK-1 required a CT or MRI showing

the absence of blood. Systemic embolism was collected as an outcome in all but SPINAF and,

by and large, defined as an embolism to internal organs or limbs and required evidence via

angiography, surgery, or autopsy (**Appendix 4**). Patients were evaluated at 3- to 6-month

intervals or when a clinical outcome event was suspected. Except in AFASAK-1, a central

committee, blinded to intervention allocation, adjudicated all clinical events.

Life expectancy

We estimated the life expectancy of each participant at the time of trial enrollment using

the life table method.[28] We started with gender- and enrollment year-specific life tables from the

U.S. Centers for Disease Control and Prevention, aggregated by the Berkeley Center for

Demography.[29] These tables, generated from population data, predict annual mortality rates

stratified by age, sex, and year. The life table method uses these stratified annual mortality rates

to calculate life expectancy. We used the life table method to estimate each participant's life

expectancy by adjusting the annual mortality rate for the additional mortality risk associated with

their comorbidities at the time of trial enrollment (**Appendix 5**).

Analysis

Guidelines recommend using the CHA_2DS_2-VASc score to estimate anticoagulation

benefit.[1–3] Thus, to speak directly to guideline-recommended clinical practice, we estimated

absolute risk reduction from anticoagulants using the CHA_2DS_2-VASc score as the base case.

Our first analytic goal was to determine if using a competing risk framework generates estimates

of stroke risk reduction different from those of the guideline-endorsed CHA$_2$DS$_2$-VASc model.

To accomplish this, we estimated the absolute risk reduction as the ACC/AHA/HRS guidelines

recommend.[1] Specifically, we assigned each patient an off-treatment risk of ischemic stroke or

systemic embolism corresponding to their CHA$_2$DS$_2$-VASc score. Rates come from the 2012

study by Friberg et al., which used the Swedish Atrial Fibrillation cohort to validate off-treatment

thromboembolic rates corresponding to each CHA$_2$DS$_2$-VASc score.[30] These rates are used in

patient-facing decision tools, online calculators, and decision analytic models.[5,31,32] To calculate

the absolute risk reduction, we multiplied the off-treatment stroke rate by 0.64, the efficacy of

anticoagulants by Hart et al.[6] Using this procedure for each patient, we estimated the annual

absolute risk reduction; this precise method is endorsed by the ACC/AHA/HRS Atrial Fibrillation

management guidelines to estimate benefit.[1] Because patients and physicians prefer to make

anticoagulant decisions using a 1-to-5-year time horizon,[5] we extrapolated this annual reduction

over five years. To account for the declining population at-risk when estimating absolute risk

reduction from the baseline stroke annual rate, we used the following standard formula:

$ARR\ in\ year\ Y = 1 - \exp(-annual\ stroke\ rate * 0.64 * Y).$[33,34(pp34-36)] The same approach is also

used in decision aids.[5]

Next, we estimated the absolute risk reduction using the Fine-Gray extension of the Cox

proportional hazards model, treating death unrelated to ischemic stroke or systemic embolism

as a competing event.[11] We fit a Fine-Gray model where time to ischemic stroke or systemic

embolism is a function of age (<65 years, 65-74 years, >75years), gender, congestive heart

failure, diabetes, hypertension, prior stroke or transient ischemic attack, and vascular disease

stratified by randomization to oral anticoagulants. We chose these covariates since they are the

same inputs used in the CHA$_2$DS$_2$-VASc score. We then used the resulting treatment-stratified

models to estimate the cumulative incidence of ischemic stroke or systemic embolism for each

participant given their covariates at each study time point, assuming first they had been

randomized to oral anticoagulants and then assuming they had been randomized to control (i.e.,

predicted values).[35,36] The difference between the two estimates represented the ARR for a

given patient at a given time point. We determined the misestimation of the CHA_2DS_2-VASc

method as the difference between the ARR estimated by CHA_2DS_2-VASc and the ARR

estimated by the Competing Risk Model. We used the paired t-test to determine if the two

methods produced statistically different estimates of benefit at each year after randomization.

Our second analytic goal was to determine if life expectancy predicted variation in the

CHA_2DS_2-VASc model misestimation. To achieve this, we determined the association between

life expectancy and misestimation of the CHA_2DS_2-VASc method over a 3-year horizon. We

chose 3 years since it is the midpoint between the 1-to-5 year horizon preferred by patients and

physicians and has been used in prior anticoagulation decision analyses.[5,37] We examined

misestimation of the CHA_2DS_2-VASc method by decile of life expectancy at trial enrollment,

hypothesizing that the misestimation would be greater at lower life expectancies.

We performed all statistical analyses using SAS 9.4 (Cary, NC). This study protocol was

approved by the University of California, San Francisco Human Subjects Research Committee

(21-34930), and Massachusetts General Hospital (2022P001783).

<u>Patient and public involvement</u>

Patients were not involved in the design, conduct, or reporting of this study. The UCSF

Patient and Family Advisory Council has advised on how best incorporation of the study findings

(i.e., stroke rates) into patient-facing decision aids.

Results

<u>Patient characteristics and overall event rates</u>

This study included 7933 patients from 12 randomized trials where 3407 (43%) were

randomized to oral anticoagulation (**Table 1**). The median age was 73 years at enrollment, 36%

were women, and the median CHA_2DS_2-VASc score was 3 [IQR 2, 4]. At enrollment, the

median life expectancy was 8 years [IQR 6, 12] (**Appendix 6**). Most patients (83%) ended the

follow-up period without a clinical event (median follow-up time 731 days, IQR [415, 1025]).

(**Table 2**). In these trials, 530 (7%) patients' first clinical event was an ischemic stroke or

systemic embolism (median time to event 334 days [IQR 120, 580]). Additionally, 630 (8%)

patients died before any other clinical event (median time event 457 days [IQR 216, 772]).

<u>Relative hazard of ischemic stroke and systemic embolism</u>

Anticoagulants were effective at reducing the relative hazard of ischemic stroke and

systemic embolism (**Appendix 7**). The Fine-Gray model, which treated death as a competing

event, estimated anticoagulants reduced the hazard of ischemic or systemic embolism by 61%

compared to placebo and antiplatelets (hazard ratio 0.39, 95% CI 0.31 to 0.49).

<u>Comparison of absolute risk reduction estimates</u>

Relative to the Competing Risk Model, the CHA_2DS_2-VASc model overestimated the

absolute risk reduction (ARR) of anticoagulants (**Figure 1, Appendix 9**). As the time horizon

increased, the CHA_2DS_2-VASc estimate of median benefit increased linearly. In contrast, in the

Competing Risk Model estimated a non-linear absolute risk reduction over time—while benefit

increased over time, it decelerated, i.e., absolute risk reduction grew by less each year. As a

result, the CHA_2DS_2-VASc model overestimated anticoagulation benefit as the time-horizon

increased. After 1 year, the CHA_2DS_2-VASc model and the Competing Risk Model produced

clinically similar estimates of absolute risk reduction, although the CHA_2DS_2-VASc estimate was

statistically smaller (median ARR 2.3% vs. 2.4%, p<0.001). After 3 years, the CHA_2DS_2-VASc-

based ARR was clinically and statistically larger than the Competing Risk Model (median ARR

6.9% vs. 5.2%, p<0.001). This difference increased when absolute risk reduction was estimated

over a 5-year horizon (median ARR 11.2% vs. 6.3%, p<0.001).

In a sensitivity analysis, we assessed the possibility that because the guideline

estimates of absolute risk reduction were developed in external cohorts, they may be

miscalibrated (**Appendix 8**). The sensitivity analysis shows that recalibrating the absolute risk

reduction of CHA_2DS_2-VASc score in the AFI database does not meaningfully change the

results presented in **Figure 1**.

<u>Life expectancy and misestimation of benefit</u>

As life expectancy decreased, the CHA_2DS_2-VASc model increasingly overestimated the

stroke and systemic embolism risk reduction attributable to anticoagulants in absolute and

relative terms (**Figure 2**). The figure plots the absolute and relative difference between the 3-

year ARR estimated by the CHA_2DS_2-VASc model and the Competing Risk Model by life

expectancy decile at trial enrollment. In the decile with the highest life expectancy (16 to 47

years), on average, over 3 years, the CHA_2DS_2-VASc model underestimated benefit by 1.2%

(95% CI 1.1% to 1.3%) in absolute terms and 42% (95% CI 40% to 45%) in relative terms. By

comparison, in the decile with the lowest life expectancy (1 to 4 years), on average over 3

years, the CHA_2DS_2-VASc model overestimated benefit by 5.9% (95% CI 5.6% to 6.1%) in

absolute terms and 91% (95% CI 87% to 95%) in relative terms.

Discussion

Using patient-level data from 12 randomized trials, we demonstrated that while

anticoagulants effectively reduce ischemic stroke and systemic embolism risk, failing to use a

competing risks framework resulted in a meaningful overestimation of treatment benefit. This

finding was most pronounced when risk reduction was estimated over a multi-year horizon.

Further, we showed that as life expectancy decreased, treatment benefit was increasingly

overestimated. While those with the highest life expectancy may benefit more than guideline

estimates would suggest, benefit for those with the lowest life expectancy was strikingly

overestimated.

The study results directly apply to the AHA/ACC/HRS[1,2] and European Society of

Cardiology (ESC)[3] atrial fibrillation guidelines in which the cornerstone of anticoagulant

decision-making is estimating the absolute risk reduction. Guidelines ask clinicians to estimate

the off-treatment stroke risk using the CHA_2DS_2-VASc score and to use that baseline risk to

infer the probable absolute risk reduction. Anticoagulants are recommended above a CHA_2DS_2-

VASc score threshold—i.e., when the absolute risk reduction exceeds a threshold. Thus, if

clinical guidelines continue to recommend treatment using an absolute risk reduction threshold,

these results suggest guidelines should re-estimate benefit using a competing risk framework.

At the very least, guidelines should acknowledge that current methods overestimate benefits for

those with limited life expectancy and when estimating benefits over a multi-year horizon.

The current study's findings should influence anticoagulant decision aids for patients

with atrial fibrillation. To advance anticoagulant shared decision-making, investigators and

professional societies have developed conversation aids that display a patient's risk of stroke

with and without anticoagulants. For example, the American College of Cardiology's

CardioSmart tool and the Mayo Clinic Anticoagulation Choice Decision Aid both display a

pictogram of absolute risk with and without treatment to communicate treatment effects.[4,5]

These implementation tools are built to reflect clinical guidelines and do so faithfully. However,

both should note that benefit estimates are overstated for those with limited life expectancy and

when benefit is estimated over a multi-year horizon.

These results also lend credence to physicians for whom advanced age, frailty, and

function—all significant determinants of life expectancy—factor in their anticoagulant decision-

making.[38,39] Adults aged 65 years and older constitute 80% of all American adults with atrial

fibrillation.[40] Further, prior work indicates that upwards of 80% of older adults with atrial

fibrillation have geriatric syndromes (e.g., dependency in activities of daily living) known to be

associated with a reduced life expectancy.[12,13] In this study, we estimated life expectancy using

basic medical comorbidity data available in the trial database. Modern, more accurate tools go

beyond comorbidities using physical function, cognition, and self-reported health to estimate life

expectancy.[41,42] Life expectancy estimates from such tools are routinely used to inform the risk

and benefits of interventions in older adults (e.g., cancer screening). Until guidelines formally

account for it, clinicians may consider estimating life expectancy to guide the discussion about

the benefit of anticoagulants when treating older adults. This may be particularly relevant when

treating patients with both a limited life expectancy and borderline CHA_2DS_2-VASc scores.

Finally, these findings should inform the methods used to develop and validate future

stroke risk models. While the CHA_2DS_2-VASc score continues to be endorsed by U.S. and

European guidelines, investigators are actively developing a new generation of stroke risk

prediction models. Contemporary models like the ABC stroke risk score, CARS, and the ATRIA

stroke model all outperform the CHA_2DS_2-VASc score.[43–45] However, none used an analysis

framework that both accounts for the competing risk of death and changing risk over a multi-

year horizon. The ABC model establishes a non-linear stroke risk by showing 3-year risk is not

simply three times the 1-year risk, findings that were redemonstrated in this paper. When

developing the ABC model, Hijazi et al. also conducted a sensitivity analysis comparing their

model to a competing risk model.[43] They found a tight correlation when risk was estimated over

a 1-year horizon, results mirrored in this study. We expanded on their work by showing that this

correlation was weaker when using a longer time horizon (e.g., 3 years). More importantly, we

identified substantial heterogeneity—as life expectancy decreased, overestimation increased.

269   There are limitations to this study inherent to the data available and the study design.

First, this study relied on data from RCTs conducted between 1989 and 2007 and thus may be

only partially representative of contemporary patients with atrial fibrillation. Specific differences

include the risk of stroke and death from non-atrial fibrillation causes and the added safety of

direct-acting anticoagulants.[46] This limitation is balanced by the fact that the AFI cohort is one of

the largest patient-level atrial fibrillation cohorts where anticoagulant treatment was randomized.

The results were unaffected by selection bias that hampers contemporary risk models

developed in observational cohorts. More importantly, while dated, these trials are the

foundation upon which current guidelines recommend anticoagulants. Second, this study could

not address the relationship between life expectancy and the misestimation of anticoagulant

harm. Specifically, the AF Investigators database does not include inputs used in contemporary

hemorrhage prediction tools (e.g., ATRIA bleed, HAS-BLED). While it is important to consider

the effect a competing risk framework may have on estimating the risk of bleeding, current

guidelines do not incorporate bleeding risk into treatment recommendations. For example, for

patients with scores above the CHA_2DS_2-VASc treatment threshold, guideline recommendations

do not change whether the bleeding risk is high or low. Finally, because nationality was

unavailable for study participants, we relied on U.S. life tables to calculate life expectancy.

286   In summary, we showed that while oral anticoagulants were effective, treatment benefit

was overstated when using the guideline-endorsed approach because guidelines do not

account for the competing risk of death and assume a constant growth in treatment benefit over

time. Overestimation was most pronounced in patients with the lowest life expectancy and when

benefit was estimated over a multi-year horizon. These findings should inform guidelines and

decision aids, clinicians treating patients with limited life expectancy, and investigators

developing stroke risk prediction models.

ACKNOWLEDGMENTS

We thank Dr. Sei Lee, Professor of Medicine at UCSF, for his valuable methodological feedback. Dr. Shah had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Conflict of Interest Disclosure: Dr. Shah, Dr. Jeon, Dr. Boscardin, and Dr. Covinsky reported funding from the National Institute on Aging/National Institutes of Health related to the conduct of this study (noted below). Dr. Fang reported grants from the National Heart, Lung, and Blood Institute/National Institutes of Health during the conduct of the study (K24HL141354) and grants from Patient-Centered Outcomes Research Institute outside the submitted work. Dr. Singer was supported, in part, by the Eliot B. and Edith C. Shoolman Fund of Massachusetts General Hospital. He has received research support from Bristol Myers Squibb and consultancy fees from Bristol-Myers Squibb, Fitbit, Medtronic, and Pfizer. Professor Hobbs is, in part, supported by the NIHR (ARC OTV and MIC) and has received occasional consultancy fees from Bayer, BMS Pfizer, Novartis, and AZ unconnected to this study.

Funding: This study was funded by the NIA (K76AG074919, P30AG044281).

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data sharing: Researchers can apply to the AF Investigators for data access.

Ethical review: The Committee on Human Research at the University of California, San Francisco, and the Partners Human Research Committee at Massachusetts General Hospital approved the analysis for this study and waived the requirement for patient consent (Protocol 21-35046 and 2022P001783, respectively).

References

1. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol.* 2014;64(21):e1-e76. doi:10.1016/j.jacc.2014.03.022

2. January C, Wann L. Samuel, Calkins Hugh, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. *Circulation.* 2019;140(2):e125-e151. doi:10.1161/CIR.0000000000000665

3. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J.* 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612

4. Atrial Fibrillation | CardioSmart – American College of Cardiology. CardioSmart. Accessed December 23, 2020. http://www.cardiosmart.org/topics/atrial-fibrillation

5. Zeballos-Palacios CL, Hargraves IG, Noseworthy PA, et al. Developing a Conversation Aid to Support Shared Decision Making: Reflections on Designing Anticoagulation Choice. *Mayo Clin Proc.* 2019;94(4):686-696. doi:10.1016/j.mayocp.2018.08.030

6. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. *Ann Intern Med.* 2007;146(12):857-867. doi:10.7326/0003-4819-146-12-200706190-00007

7. Austin PC, Fine JP. Accounting for competing risks in randomized controlled trials: a review and recommendations for improvement. *Stat Med.* 2017;36(8):1203-1209. doi:10.1002/sim.7215

8. Koller MT, Raatz H, Steyerberg EW, Wolbers M. Competing risks and the clinical community: irrelevance or ignorance? *Stat Med.* 2012;31(11-12):1089-1097. doi:10.1002/sim.4384

9. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks in survival data analysis. *Br J Cancer.* 2004;91(7):1229-1235. doi:10.1038/sj.bjc.6602102

10. Berry SD, Ngo L, Samelson EJ, Kiel DP. Competing Risk of Death: An Important Consideration in Studies of Older Adults. *J Am Geriatr Soc.* 2010;58(4):783-787. doi:10.1111/j.1532-5415.2010.02767.x

11. Austin Peter C., Lee Douglas S., Fine Jason P. Introduction to the Analysis of Survival Data in the Presence of Competing Risks. *Circulation.* 2016;133(6):601-609. doi:10.1161/CIRCULATIONAHA.115.017719

12. Shah SJ, Fang MC, Jeon SY, Gregorich SE, Covinsky KE. Geriatric Syndromes and Atrial Fibrillation: Prevalence and Association with Anticoagulant Use in a National Cohort of Older Americans. *J Am Geriatr Soc.* 2021;69(2):349-356. doi:10.1111/jgs.16822

13. Kane RL, Shamliyan T, Talley K, Pacala J. The Association Between Geriatric Syndromes and Survival. *J Am Geriatr Soc.* 2012;60(5):896-904. doi:10.1111/j.1532-5415.2012.03942.x

14. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. *J Am Stat Assoc.* 1999;94(446):496-509. doi:10.2307/2670170

15. Petersen P, Godtfredsen J, Boysen G, Andersen E, Andersen B. PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION: The Copenhagen AFASAK Study. *The Lancet.* 1989;333(8631):175-179. doi:10.1016/S0140-6736(89)91200-2

16. Gulløv AL, Koefoed BG, Petersen P, et al. Fixed Minidose Warfarin and Aspirin Alone and in Combination vs Adjusted-Dose Warfarin for Stroke Prevention in Atrial Fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. *Arch Intern Med.* 1998;158(14):1513-1521. doi:10.1001/archinte.158.14.1513

17. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators, Singer DE, Hughes RA, et al. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. *N Engl J Med.* 1990;323(22):1505-1511. doi:10.1056/NEJM199011293232201

18. Mant J, Hobbs FR, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. *The Lancet.* 2007;370(9586):493-503. doi:10.1016/S0140-6736(07)61233-1

19. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian atrial fibrillation anticoaguiation (CAFA) study. *J Am Coll Cardiol.* 1991;18(2):349-355. doi:10.1016/0735-1097(91)90585-W

20. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. *The Lancet.* 1993;342(8882):1255-1262. doi:10.1016/0140-6736(93)92358-Z

21. Hellemons BSP, Langenberg M, Lodder J, et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. *BMJ.* 1999;319(7215):958-964. doi:10.1136/bmj.319.7215.958

22. Pérez-Gómez F, Alegría E, Berjón J, et al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: A randomized multicenter study. *J Am Coll Cardiol.* 2004;44(8):1557-1566. doi:10.1016/j.jacc.2004.05.084

23.   Preliminary Report of the Stroke Prevention in Atrial Fibrillation Study. *N Engl J Med*. 1990;322(12):863-868. doi:10.1056/NEJM199003223221232

24.   Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. *The Lancet*. 1994;343(8899):687-691. doi:10.1016/S0140-6736(94)91577-6

25.   Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. *The Lancet*. 1996;348(9028):633-638. doi:10.1016/S0140-6736(96)03487-3

26.   Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. *N Engl J Med*. 1992;327(20):1406-1412. doi:10.1056/NEJM199211123272002

27.   White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. *Stat Med*. 2011;30(4):377-399. doi:https://doi.org/10.1002/sim.4067

28.   *Method for Constructing Complete Annual U.S. Life Tables*. National Center for Health Statistics; 1999:36.

29.   The Berkeley Mortality Database. Accessed November 3, 2021. http://bmd.mortality.org/

30.   Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. *Eur Heart J*. 2012;33(12):1500-1510. doi:10.1093/eurheartj/ehr488

31. CHA_2DS_2-VASc Score for Atrial Fibrillation Stroke Risk - MDCalc. Accessed October 11, 2022. https://www.mdcalc.com/calc/801/cha2ds2-vasc-score-atrial-fibrillation-stroke-risk

32.   Eckman MH, Wise RE, Naylor K, et al. Developing an Atrial Fibrillation Guideline Support Tool (AFGuST) for shared decision making. *Curr Med Res Opin*. 2015;31(4):603-614. doi:10.1185/03007995.2015.1019608

33.   Miller DK, Homan SM. Determining Transition Probabilities: Confusion and Suggestions. *Med Decis Making*. 1994;14(1):52-58. doi:10.1177/0272989X9401400107

34.   Rothman KJ. *Epidemiology: An Introduction*. Oxford University Press; 2002. https://books.google.com/books?id=f3gItAEACAAJ

35.   Bieler GS, Brown GG, Williams RL, Brogan DJ. Estimating Model-Adjusted Risks, Risk Differences, and Risk Ratios From Complex Survey Data. *Am J Epidemiol*. 2010;171(5):618-623. doi:10.1093/aje/kwp440

36.   Graubard BI, Korn EL. Predictive Margins with Survey Data. *Biometrics*. 1999;55(2):652-659. doi:10.1111/j.0006-341X.1999.00652.x

37.   Shah Sachin J., Singer Daniel E., Fang Margaret C., Reynolds Kristi, Go Alan S., Eckman Mark H. Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial

Fibrillation. *Circ Cardiovasc Qual Outcomes*. 2019;12(11):e006212. doi:10.1161/CIRCOUTCOMES.119.006212

38. Ashburner JM, Atlas SJ, Khurshid S, et al. Electronic physician notifications to improve guideline-based anticoagulation in atrial fibrillation: a randomized controlled trial. *J Gen Intern Med*. Published online August 3, 2018. doi:10.1007/s11606-018-4612-6

39. McGrath ER, Go AS, Chang Y, et al. Use of Oral Anticoagulant Therapy in Older Adults with Atrial Fibrillation After Acute Ischemic Stroke. *J Am Geriatr Soc*. 2017;65(2):241-248. doi:10.1111/jgs.14688

40. Go AS, Hylek EM, Phillips KA, et al. Prevalence of Diagnosed Atrial Fibrillation in Adults: National Implications for Rhythm Management and Stroke Prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. *JAMA*. 2001;285(18):2370-2375. doi:10.1001/jama.285.18.2370

41. Lee SJ, Lindquist K, Segal MR, Covinsky KE. Development and Validation of a Prognostic Index for 4-Year Mortality in Older Adults. *JAMA*. 2006;295(7):801-808. doi:10.1001/jama.295.7.801

42. Schonberg MA, Davis RB, McCarthy EP, Marcantonio ER. Index to Predict 5-Year Mortality of Community-Dwelling Adults Aged 65 and Older Using Data from the National Health Interview Survey. *J Gen Intern Med*. 2009;24(10):1115-1122. doi:10.1007/s11606-009-1073-y

43. Hijazi Z, Lindbäck J, Alexander JH, et al. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. *Eur Heart J*. 2016;37(20):1582-1590. doi:10.1093/eurheartj/ehw054

44. Lee CJY, Toft-Petersen AP, Ozenne B, et al. Assessing absolute stroke risk in patients with atrial fibrillation using a risk factor-based approach. *Eur Heart J - Cardiovasc Pharmacother*. 2021;7(FI1):f3-f10. doi:10.1093/ehjcvp/pvaa063

45. Singer DE, Chang Y, Borowsky LH, et al. A New Risk Scheme to Predict Ischemic Stroke and Other Thromboembolism in Atrial Fibrillation: The ATRIA Study Stroke Risk Score. *J Am Heart Assoc*. 2013;2(3):e000250. doi:10.1161/JAHA.113.000250

46. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *The Lancet*. 2014;383(9921):955-962.

47. Arias E, Escobedo LA, Kennedy J, Fu C, Cisewski JA. U.S. small-area life expectancy estimates project : methodology and results summary. National Center for Health Statistics (U.S.), ed. Published online September 2018. https://stacks.cdc.gov/view/cdc/58853

Table 1: Characteristics of patients with atrial fibrillation in 12 randomized trials

Characteristic	n=7933
Age, years (median [IQR])	73 [67, 78]
Gender	
Male	5040 (64%)
Female	2893 (36%)
Diabetes	
No	6780 (85%)
Yes	1153 (15%)
Hypertension	
No	4049 (51%)
Yes	3884 (49%)
Congestive heart failure	
No	5533 (70%)
Yes	2400 (30%)
Prior stroke	
No	6413 (81%)
Yes	1520 (19%)
Angina	
No	6566 (83%)
Yes	1367 (17%)
Prior myocardial infarction	
No	6514 (82%)
Yes	876 (11%)
Missing*	543 (7%)
Peripheral vascular disease	
No	5109 (64%)
Yes	429 (5%)
Missing†	2395 (30%)
Body mass index kg/m² (median [IQR])	
BMI among those with data	26 [24, 29]
Missing‡	2070 (26%)
Smoking status	
Never smoker	2427 (31%)
Former smoker	1843 (23%)
Current smoker	790 (10%)
Missing§	2873 (36%)
CHA_2DS_2-VASc score	

Score (median [IQR])	3 [2, 4]
Missing[–]	2938 (37%)
Trial	
AFASAK1	1002 (13%)
AFASAK2	677 (9%)
BAATAF	420 (5%)
BAFTA	973 (12%)
CAFA	375 (5%)
EAFT	661 (8%)
NASPEAF	543 (7%)
PATAF	364 (5%)
SPAF1	208 (3%)
SPAF2	1098 (14%)
SPAF3	1044 (13%)
SPINAF	568 (7%)
Randomized study arm assignment	
Warfarin	3407 (43%)
Control[¶]	4526 (57%)

Legend

AFASAK - Atrial Fibrillation, Aspirin, and Anticoagulation Study; BAATAF - Boston Area Anticoagulation Trial for Atrial Fibrillation; BAFTA - Birmingham Atrial Fibrillation Treatment of the Aged Study; CAFA - Canadian Atrial Fibrillation Anticoagulation; EAFT - European Atrial Fibrillation Trial; PAATAF - Primary Prevention of Arterial Thromboembolism in Atrial Fibrillation; NASPEAF - National Study for Prevention of Embolism in Atrial Fibrillation; SPAF - Stroke Prevention in Atrial Fibrillation; SPINAF - Stroke Prevention in Non-rheumatic Atrial Fibrillation

* History of myocardial infarction was not available for NSPEAF trial participants

† History of peripheral vascular disease was not available for AFASAK1, BAATAF, or BAFTA trial participants

‡ Height and weight were not available for BAATAF or AFASAK2 trial participants

§ Smoking status was not available for AFASAK1, CAFA, or BAFTA participants. In EAFT, data collection did not distinguish between former and never smokers

▯ CHA_2DS_2-VASc scores are for those with complete cases. It excludes 2395 participants enrolled in trials where peripheral vascular disease data are not available, and 543 participants enrolled in trials where history of myocardial infarction was not available.

¶ Control includes those assigned placebo, aspirin, low-dose warfarin, or low-dose warfarin an aspirin. Patients enrolled in SPAF3 and AFASAK2 and assigned to low-dose warfarin had a mean internal normalized ratio (INR) of < 1.5 supporting their categorization as a control. Patients enrolled in NASPEAF and randomized to low-dose anticoagulant had a mean INR of 2.0 and were therefore not included as a control.

Since missing data were missing for entire trials, they were assumed to be missing completely at random.

Table 2: Trial outcomes, rates and follow-up time

First clinical outcome	Events (%)	Days from randomization, median (IQR)
Ischemic stroke or systemic embolism	530 (7%)	334 (120, 580)
Systemic bleed	175 (2%)	413 (163, 731)
Intracranial hemorrhage	29 (0%)	300 (201, 620)
Death, all-cause	630 (8%)	457 (216, 772)
Study end without a clinical event	6569 (83%)	731 (415, 1025)

Figure 1: Estimated median absolute risk reduction by CHA$_2$DS$_2$-VASc model compared with Competing Risk Model

<u>Legend</u>

For each patient in the cohort, we estimate the absolute risk reduction attributable to oral anticoagulation annually for 5 years using the CHA$_2$DS$_2$-VASc model and again using a Fine-Gray model, a survival model that accounts for the competing risk of death. We plot the median benefit at each time point. We graphed the median ARR because the CHA$_2$DS$_2$-VASc model produces discrete estimates of benefit (i.e., not normally distributed). Data are presented as a table in Appendix 9. Component on- and off-treatment cumulative incidence rates also displayed in Appendix 9.

Figure 2: Misestimation of Stroke Risk Reduction by CHA$_2$DS$_2$-VASc score at 3 years,

(A) Absolute misestimation $(\text{ARR}_{\text{CHA2DS2-VASc}} - \text{ARR}_{\text{Competing Risk Model}})$

(B) Relative misestimation $(\text{ARR}_{\text{CHA2DS2-VASc}} / \text{ARR}_{\text{Competing Risk Model}} - 1)$

Legend

The dot represents the mean overestimation, and the error bars represent the 95% confidence interval of the mean. The misestimation of absolute risk reduction (ARR) is calculated for each patient as the difference between the ARR computed by the $\text{CHA}_2\text{DS}_2\text{-VASc}$ score and the ARR computed by the Fine-Gray model, a survival model that accounts for the competing risk of death. Positive numbers represent the overestimation of the $\text{CHA}_2\text{DS}_2\text{-VASc}$ model. Tabular results can be found in Appendix 10.

Appendix

Appendix 1: Trial inclusion and exclusion criteria and study period

Trial	Inclusion	Exclusion	Trial period
Atrial Fibrillation, Aspirin, and Anticoagulation Study 1 (AFASAK-1)[15]	≥18 years old ECG-verified atrial fibrillation Primary physician consent	Anticoagulation for >6 months Cerebrovascular event within the past month Contraindications for aspirin or warfarin therapy Previous side-effects of aspirin or warfarin therapy Pregnancy or breastfeeding Persistent BP > 180/100 mmHg Psychiatric diseases Chronic alcoholism Heart surgery with valve replacement Rheumatic heart disease	Nov 1985 to Jun 1988
AFASAK-2[16]	≥18 years old AF on 2+ ECGs at least 1 month apart	Age < 60 years with lone AF (i.e., with no underlying ischemic or hypertensive heart disease, congestive heart failure, hyperthyroidism, or chronic obstructive pulmonary disease) Mitral stenosis SBP >180 mm Hg DBP >100 mm Hg Stroke or TIA within 6 months Risk factors for bleeding risk factors Contraindication to warfarin or aspirin Already receiving dose-adjusted warfarin Mitral stenosis Atrial flutter	May 1993 to Oct 1996
Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)[17]	AF on 2+ ECG No evidence of mitral stenosis on echocardiography	Intermittent AF with no ECG with AF within 18 months Transient AF during acute illness Planned cardioversion Echocardiographic evidence of intracardiac thrombus, ventricular aneurysm, severe congestive heart failure or prosthetic valve Stroke <6 months ago predisposition to intracranial hemorrhage TIA requiring treatment Predisposition to intracranial hemorrhage Indication or contraindication for anticoagulation Required aspirin therapy Abnormal thyroid function tests	Sept 1985 to Apr 1990

Trial	Inclusion	Exclusion	Trial period
Birmingham Atrial Fibrillation Treatment of the Aged Study (BAFTA)[18]	Age ≥75 years; atrial fibrillation or atrial flutter on an ECG within the past 2 years	Rheumatic heart disease Major nontraumatic hemorrhage within 5 years Intracranial hemorrhage Peptic ulcer disease by endoscopy in the last year Esophageal varices Allergy to warfarin or aspirin Terminal illness as judged by primary care physician Surgery within past 3 months BP >180/110 mmHg Primary care physician judged that the patient should or should not be on warfarin (i.e., no equipoise)	Apr 2001 to Sept 2006
Canadian Atrial Fibrillation Anticoagulation (CAFA)[19]	Chronic atrial fibrillation for ≥ 1 month or paroxysmal atrial fibrillation ≥3 times in previous 3 months (documented at least twice on ECG) Age ≥19 years old Absences of mitral valve prosthesis or mechanical aortic valve prosthesis Absence of mitral valve stenosis on echocardiography	Requirement for anticoagulation Contraindication to anticoagulation Stroke or TIA within the past year Requirement for antiplatelet drug therapy Hyperthyroidism Uncontrolled hypertension Myocardial infarction within the past month	Jun 1987 to Apr 1990
European Atrial Fibrillation Trial (EAFT)[20]	Age >25 years old TIA or minor stroke (grade 3 or less on modified Rankin scale) in previous 3 months Atrial fibrillation at the time of TIA/stroke or paroxysmal atrial fibrillation in preceding 24 months No rheumatic valvular disease on echocardiography	Atrial fibrillation secondary to other illness (e.g., hyperthyroidism) Indication or contraindication for aspirin NSAID medication use Antiplatelet medication use Oral anticoagulation use No other cardioembolic source (e.g., prosthetic valve, cardiac aneurysm, atrial myxoma, cardiothoracic ration > 0.65, myocardial infarction in preceding 3 months, disorders of blood coagulation) Scheduled for carotid endarterectomy or coronary surgery in next 3 months	Oct 1988 to Apr 1993

Trial	Inclusion	Exclusion	Trial period
Primary Prevention of Arterial Thromboembolism in Atrial Fibrillation (PAATAF)[21]	Age ≥60 years Chronic or intermittent atrial fibrillation on ECG in past 2 years	Treatable causes of AF Previous stroke Rheumatic valve disease MI or cardiovascular surgery in past 1 year Cardiomyopathy with left ventricular ejection fraction <40% Chronic heart failure Cardiac aneurysm Previous systemic or retinal infarction Coumarin use in past 3 months Contraindications to aspirin or coumarin (hemoglobin concentration < 7.0 mmol/l, ventricular or duodenal ulcer in the past three years, gastrointestinal or urogenital bleeding in the past year, aspirin intolerance, coagulation disorder, and severe hepatic or renal disease) Pacemaker Life expectancy <2 years Additional exclusion for standard anticoagulation: age ≥ 78 years, retinopathy, ventricular or duodenal ulcer, history of gastrointestinal hemorrhage, genitourinary bleeding, BP > 185/105 mm Hg	Jan 1990 to Dec 1996
National Study for Prevention of Embolism in Atrial Fibrillation (NASPEAF)[22]	Chronic or documented paroxysmal atrial fibrillation Age > 60 years High risk by SPAF3 criteria: - Impaired left ventricle manifested by congestive heart failure within 100 days or fractional shortening ≤ 25% - Systolic blood pressure >160 mm Hg on one reading and >150 mm Hg on second reading or documented systolic blood pressure >160 mm Hg in preceding 3 months - Prior ischemic stroke, TIA, or systemic embolism more than 30 days prior to entry - Female and age over 75 years	Mechanical valve prosthesis Stroke in previous 6 months Serum creatinine >3 mg/dL Alcoholism or drug addiction Severe uncontrolled hypertension Indication for NSAIDs Indication or contraindication for antiplatelet or anticoagulant therapy	Jun 1995 to Jun 2001

Trial	Inclusion	Exclusion	Trial period
Stroke Prevention in Atrial Fibrillation 1 study (SPAF-1)[23]	AF on ECG (constant or intermittent) in the preceding 12 months	Prosthetic heart valve Personal physician refuses study No echocardiographic evidence of rheumatic mitral stenosis Successful cardioversion (electrical or chemical) NYHA class IV congestive heart failure Mitral regurgitation with congest heart failure and atrial diameter >5.5 cm Idiopathic cardiomyopathy with congestive heart failure Myocardial infarction in preceding 3 months Coronary bypass surgery within previous 1 year Coronary angioplasty within previous 3 months Unstable angina within previous 1 year Stroke, TIA, carotid endarterectomy in previous 24 months Life expectancy < 24 months due to other medical condition Chronic renal failure with serum creatinine > 3.0 mg/dL Thrombocytopenia with platelet count < 100,000 platelets /mm^3 Anemia with hemoglobin concentration < 10 g/dL Severe chronic alcohol habituation Indication or contraindication for warfarin or aspirin therapy Treatment with non-steroidal anti-inflammatory drugs Additional exclusion from anticoagulation arm: - On antihypertensive therapy and SBP>180 mm Hg and DBP > 100 mm Hg - Prothrombin time > 2 seconds on 2 occasions - Stool test positive for occult blood - Inability to obtain follow up for prothrombin time monitoring - Previous intracranial hemorrhage, gastrointestinal, or genitourinary bleeding within previous 6 months - Previous severe hemorrhage with therapeutic anticoagulation - Lone AF (age<60 years, left atrial size <2.1 cm/m^2, no associated cardiopulmonary disease except mitral valve prolapse) - Patient or physician refuses - Age > 75 years (for patients enrolled before Nov 1988)	Jun 1987 to Nov 1989
SPAF-2[24]	AF on ECG (constant or intermittent) in the preceding 12 months	Same as reported for SPAF-1	Sept 1985 to 1992

Trial	Inclusion	Exclusion	Trial period
SPAF-3[25]	AF on ECG within 6 months 1 or more high risk features: - Impaired left ventricle manifested by congestive heart failure within 100 days or fractional shortening ≤ 25% - Systolic blood pressure >160 mm Hg on one reading and >150 mm Hg on second reading or documented systolic blood pressure >160 mm Hg in preceding 3 months - Prior ischemic stroke, TIA, or systemic embolism more than 30 days prior to entry - Female and age over 75 years	Same as reported for SPAF-1	May 1993 to Oct 1995
Stroke Prevention in Non-rheumatic Atrial Fibrillation (SPINAF)[26]	Male No echocardiographic evidence of rheumatic heart disease AF on 2 ECGs at least 4 weeks apart Normal prothrombin time ratio	Intermittent AF Definite indication for anticoagulant or antiplatelet Chronic alcoholism, social or psychological condition unsuitable to anticoagulation Co-existing medical disorder Hemostasis disorder Peptic ulcer disease within 2 years, esophageal varices, history of intracranial hemorrhage History of gastrointestinal hemorrhage within 2 years Planned surgery or invasive procedure Lab abnormalities (Hct <32%, platelet count <100,000 /mm3, AST, ALT, or alkaline phosphatase > 2x ULN, guaiac-positive stool, > 5 RBCs/hpf in urine Uncontrolled hypertension >180/105 mm Hg Bacterial endocarditis Atrial tumor Anticoagulation within 6 months ago Use of nonsteroidal anti-inflammatory Uninterpretable echocardiogram TIA within 5 years Previous cerebral infarction Hyperthyroidism Planned cardioversion Unstable angina	Jun 1987 to May 1993

Legend: AF – atrial fibrillation, ECG – electrocardiogram, SBP – systolic blood pressure, DBP – diastolic blood pressure, BP – blood pressure, TIA – transient, ischemic attack, NSAID – nonsteroidal anti-inflammatory drug, NYHA – New York Heart Association, ULN – upper limit of normal

Appendix 2: Trial arms and enrollment

Trial	Mean observation time	Anticoagulant arm(s)	Antiplatelet arm	Combination	Placebo arm
Atrial Fibrillation, Aspirin, and Anticoagulation Study 1 (AFASAK-1)[15]	1.3 yrs	Dose adjusted warfarin with goal INR 2.8-4.2 (N = 335)	Aspirin 75 mg/d (N = 336)	n/a	N = 336
AFASAK-2[16]	1.6 yrs	Fixed dose warfarin 1.25mg/d (N=167)* Dose-adjusted warfarin with goal INR 2.0-3.0 (N=170)	Aspirin 300 mg/d (N=169)	Fixed-dose warfarin and aspirin 300 mg/d (N=171)†	n/a
Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)[17]	2.2 years	Dose-adjusted warfarin with goal INR 1.5-2.7 (N=212) ‡	n/a	n/a	N=208
Birmingham Atrial Fibrillation Treatment of the Aged Study (BAFTA)[18]	2.7 years	Dose-adjusted warfarin with goal INR 2.0-3.0 (N=488)	Aspirin 75 mg/d (N=485)	n/a	n/a
Canadian Atrial Fibrillation Anticoagulation (CAFA)[19]	1.3 years	Dose-adjusted warfarin with goal INR 2.0-3.0 (n=187)	n/a	n/a	N=191
European Atrial Fibrillation Trial (EAFT)[20] Group 1 (eligible for anticoagulants) §	2.3 years	Dose-adjusted warfarin with goal INR 2.5-4.0 (N=225)	Aspirin 300 mg/d (N= 230)	n/a	N=214
Primary Prevention of Arterial Thromboembolism in Atrial Fibrillation (PAATAF)[21] Group 1 (eligible for anticoagulants) §	3.0 years	Dose-adjusted warfarin with goal INR 2.5-3.5 (N=131) Low-intensity coumarin with INR goal 1.1-1.6 (N=122) ▢	Aspirin 150 mg/day (N=141)	n/a	n/a
National Study for Prevention of Embolism in Atrial Fibrillation (NASPEAF)[22] ¶	2.4 years	Dose-adjusted acenocumarol with goal INR 2.0-3.0 (N=323)	Triflusal 600 mg/day (N=235)**	n/a	n/a
Stroke Prevention in Atrial Fibrillation 1 study (SPAF-1)[23] Group 1 (eligible for anticoagulants) § ††	1.2 years				N=211
SPAF-2[24]	2.7 years	Dose-adjusted warfarin with goal INR 2.0-4.5 (N=555)	Aspirin 325 mg/d (N=545)	n/a	n/a

Trial	Mean observation time	Anticoagulant arm(s)	Antiplatelet arm	Combination	Placebo arm
SPAF-3[25]	1.1 years	Dose adjusted warfarin with goal INR 2.0 to 3.0 (N=523)		Low, fixed dose warfarin (0.5 to 3.0 mg/d) to raise INR to between 1.2 and 1.5 and aspirin 325 mg/d (N=521) ‡‡	
Stroke Prevention in Non-rheumatic Atrial Fibrillation (SPINAF)[26]	1.7 years	Warfarin with goal INR 1.5 to 2.7‡ (N=265)			N=260

Legend

INR – international normalized ratio
* Trial reported a mean INR of 1.14, supporting categorization as control
† Trial reported a mean INR of 1.12, supporting categorization as control
‡ INR estimate prothrombin-time ratio
§ Group 2 were those deemed ineligible for anticoagulants and were thus excluded from the current analysis
☐ Trial reported a mean INR of 1.4 supporting categorization as control
¶ NASPEAF included patients with valvular atrial fibrillation, sample size reported here excludes those with valvular AF. Combination arms were excluded because the trial reported a median INR of 1.9 in the intermediate-risk group, and 2.1 in the high-risk group.
** Similar clinical efficacy to aspirin 300 mg/day
†† SPAF1 participants randomized to anticoagulation and aspirin were followed after the termination of SPAF1 and their results are reported in SPAF-2
‡‡ Mean INR in the fixed-dose group was 1.3 supporting categorization as control

Appendix 3: Cohort flow diagram

Randomized patients who met inclusion criteria (n= 8002)

Excluded due to missing data where the data element was otherwise collected in a trial (n=69)

- Missing height (n=41)
- Missing weight (n=27)
- Missing smoking status (n=6)
- Missing hypertension status (n=5)
- Missing diabetes status (n=4)
- Missing vascular disease status (n=3)
- Missing angina status (n=3)
- Missing heart failure status (n=1)
- Missing stroke history (n=1)
- Missing myocardial infarction history (n=1)
- Missing disenrollment date (n=1)

Final cohort

(n= 7933)

Appendix 4: Primary Trial Outcome Definition

Trial	Ischemic stroke	Systemic embolism
Atrial Fibrillation, Aspirin, and Anticoagulation Study 1 (AFASAK-1)[15]	Clinical signs or a medically confirmed history of acute onset of a neurological deficit of presumed vascular origin lasting >24hrs. CT when possible; death certificates and autopsy reports for fatal strokes.	Embolism to viscera or extremities based on symptoms relevant diagnostics test, surgery, or autopsy
AFASAK-2[16]	Acute focal neurological deficit of presumed vascular origin >24 hours; no blood on CT/MRI	Embolism to kidney, spleen, gut, lung, or extremities by angiography, surgery, or autopsy
Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)[17]	Focal neurologic deficit >24 hours without blood on CT	Assessed as an outcome but not defined; no events reported
Birmingham Atrial Fibrillation Treatment of the Aged Study (BAFTA)[18]	Focal neurological deficit >24 hours without blood on CT	Embolism to kidney, spleen, gut, or extremities by angiography, scintigraphy, surgery, or autopsy
Canadian Atrial Fibrillation Anticoagulation (CAFA)[19]	Focal neurologic deficit >24 hours with new, appropriate finding on CT, excluding lacunar events	Embolism to gut, kidney, or extremities by angiography or surgery
European Atrial Fibrillation Trial (EAFT)[20]	Focal neurologic deficit >24 hours without blood on CT	Sudden vascular insufficiency of limbs or internal organs associated with evidence of arterial occlusion, in the absence of previous obstructive disease
Primary Prevention of Arterial Thromboembolism in Atrial Fibrillation (PAATAF)[21]	Focal neurologic deficit >24 hours without blood on CT	Acute vascular occlusion resulting in recovery, permanent sequelae, or death
National Study for Prevention of Embolism in Atrial Fibrillation (NASPEAF)[22]	Focal neurologic deficit >24 hours without blood on neuroimaging	Abrupt vascular insufficiency without previous symptoms
Stroke Prevention in Atrial Fibrillation 1 study (SPAF-1)[23]	Acute focal neurological deficit in the distribution of a single brain artery lasting >24 hours; no blood on CT/MRI	Abrupt vascular insufficiency associated with clinical or radiologic evidence of arterial occlusion in the absence of other likely mechanisms (e.g., atherosclerosis, instrumentation).

Trial	Ischemic stroke	Systemic embolism
SPAF-2[24]	Focal neurological deficit of sudden onset had to persist beyond 24 hours; ischemic cause was confirmed by neuroimaging or autopsy	Abrupt vascular insufficiency related to arterial occlusion without previous obstructive disease.
SPAF-3[25]	Focal neurological symptoms or signs of sudden onset persisting for more than 24 h; the absence of primary hemorrhage was confirmed by neuroimaging or autopsy	Abrupt vascular insufficiency related to arterial occlusion without previous obstructive disease.
Stroke Prevention in Non-rheumatic Atrial Fibrillation (SPINAF)[26]	Focal neurologic deficit >12 hours without blood or tumor on CT	Not considered a primary or secondary outcome

Appendix 5 Estimation of life expectancy

5.1 Background

We estimated the life expectancy for each participant using the life table method.[47] We started with the Centers for Disease Control and Prevention life tables. We selected the sex- and enrollment year-specific life table for each participant. We modified the expected annual mortality based on the excess mortality risk associated with their baseline comorbidities for each year following trial enrollment. The following equation estimated modified mortality risk:

$$q_{xi} = 1 - e^{-1[(\sum_1^n n_i * z * q_x) + q_x]} \quad (1)$$

Where q_{xi} is the estimated 1-year mortality risk for the ith patient at a given age on or after trial enrollment. z represented the excess hazard of a patient comorbidity (indicator variable n_i) and q_x is the CDC life table mortality risk based on the patient's age, sex, and trial enrollment year. Values of z are presented in Appendix Table 5.2. We chose specific comorbidities to adjust life expectancy based on our prior studies, baseline characteristics present in the AFI database, and conditions for which published epidemiological studies on excess mortality risk exist. We used this approach in prior analyses.[37]

5.2 Table: Excess mortality risk for comorbidities adjusted for in this analysis

Condition	Subset	Excess mortality risk (z in equation 1)
Diabetes (Tancredi et al. NEJM 2015, Table 2)	< 55 years	1.32
	Age >= 55, < 65 years	0.72
	Age >= 65,< 75 years	0.42
	Age >= 75 years	0.11
Heart Failure (Roger et al. JAMA 2004 Table 3 5-yr mortality standardized against age, sex, year-specific population mortality)	Male 1979 to 1984	0.79
	Female 1979 to 1984	1.52
	Male 1985 to 1990	1.10
	Female 1985 to 1990	2.11
	Male 1991 to 1995	1.27
	Female 1991 to 1995	2.38
	Male after 1996	1.10
	Female after 1996	2.05
Stroke (Brønnum al. Stroke 2001 Table 2)	Male >= 70 years	0.92
	Male < 70 years	2.01
	Female >= 70 years	1.05
	Male < 70 years	2.52
Body Mass Index (Flegal et al. 2005 JAMA; Table 2)	BMI < 18.5 and (Age >=60, < 70 years)	1.30
	BMI 18.5 and (Age >= 70 years)	0.69
	BMI > 35 and (Age < 60 years)	0.83
	BMI > 35 and (Age >= 60, < 70 years)	0.63
Tobacco use (Carter et al. NEJM 2015; supplemental appendix C)	Current use	1.80
	Former use	0.50
Acute myocardial infarction (Norgaard et al. Diabetologia 2010; Table 2)	Male before 2001	0.40
	Female before 2001	0.87
	Male 2001 or after	0.465
	Female 2001 or after	0.91

5.3 Worked example

Consider an 80-year-old man enrolled in a trial in 1990 with a history of an acute myocardial infarction and diabetes. The baseline 1-year mortality risk for an 80-year-old male in 1990 (q_x) is 0.08542 from the CDC life table. Based on equation (1) above, this patient's individualized mortality risk (q_{xi}) would be calculated as:

$$q_{xi} = 1 - e^{-1[\,(0.40*0.08542)+(0.11*0.08542)+(0.08542)\,]}$$

$$q_{xi} = 0.12101$$

We perform the same calculation for each year for each patient following trial enrollment. Updated mortality rates are then used to calculate the patient's estimated life expectancy at trial enrollment using the life table method.

5.4 Performance of life expectancy compared to age

In the final study cohort, life expectancy and age are inversely correlated (Pearson correlation coefficient of -0.77). To determine their relative performance, we fit two separate Cox models with time to death as the outcome. The first included age as the sole predictor and the other with life expectancy as the sole predictor. We found that life expectancy has a better discriminatory capacity when predicting death at 3 years in the AFI cohort (Harrell's c-statistic 0.68 vs. 0.61).

Appendix 6: Table 1 Baseline characteristic after 20 chained imputations

Characteristic	
Age, years (median [IQR])	73 [67, 78]
Life expectancy, years (median [IQR])	8 [6, 12]
Sex	
Male	64%
Female	36%
Diabetes	
No	85%
Yes	15%
Hypertension	
No	51%
Yes	49%
Congestive heart failure	
No	70%
Yes	30%
Prior stroke	
No	81%
Yes	19%
Angina	
No	83%
Yes	17%
Prior myocardial infarction	
No	88%
Yes	12%
Peripheral vascular disease	
No	92%
Yes	8%
Body mass index kg/m^2 (median [IQR])	26 [24, 29]
Smoking status	
Never smoker	49%
Former smoker	36%
Current smoker	16%
CHA$_2$DS$_2$-VASc score (median [IQR])	3 [2, 4]
Trial	
AFASAK1	13%

BAATAF	5%
CAFA	5%
SPAF1	3%
SPINAF	7%
EAFT	8%
PATAF	5%
SPAF2	14%
AFASAK2	9%
SPAF3	13%
NASPEAF	7%
BAFTA	12%
Randomized study arm assignment	
Warfarin	43%
Control	57%

Appendix 7: Relative effectiveness of anticoagulants

Fine-gray model parameters where death is treated as a competing risk

Parameter	HR	LL	UL
Age (65-74 years, reference <65 years)	1.17	0.95	1.45
Age (75+ years, reference <65 years)	1.59	1.17	2.15
Women	1.15	0.97	1.35
History of congestive heart failure	1.12	0.89	1.42
History of hypertension	1.40	1.20	1.65
History of diabetes	1.40	1.21	1.62
History of prior stroke or TIA	3.13	2.45	4.00
History of peripheral vascular disease	1.13	0.91	1.40
Randomization to anticoagulant arm	0.39	0.31	0.49

* For interpretability, BMI and life expectancy hazard ratios are listed for the 75th percentile versus the 25th percentile.

Appendix 8 Comparing ARR estimated by CHA$_2$DS$_2$-VASc with an internally re-calibrated CHA$_2$DS$_2$-VASc ARR

8.1 Background

To calculate absolute risk reduction in the main analysis, we used the procedure detailed in the "2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation." This procedure is also used in decision aids developed by the ACC and Mayo Clinic. In brief, this method uses annual stroke rates corresponding to each CHA$_2$DS$_2$-VASc score from Friberg et al. (European Heart Journal (2012) 33, 1500–1510) and then apply a 0.64 relative risk reduction estimated by Hart et al. (Ann Intern Med. 2007;146:857-867). Together these two studies are used to estimate the absolute risk reduction attributable to therapy in guidelines and decision tools.

The main analysis compared the guideline estimate of absolute risk reduction to a Fine-Gray model that treats death as a competing event, which is estimated in the AFI database. Since the guideline estimates were developed in external cohorts, they may be miscalibrated resulting in the over-estimate of treatment benefit observed in the main analysis.

In this sensitivity analysis, we determined if the CHA$_2$DS$_2$-VASc would perform better if it were re-estimated in the AFI database. We estimate CHA$_2$DS$_2$-VASc specific stroke rates by dividing the number of events by person time. We then apply the hazard ratio of treatment from this analysis to determine the absolute risk reduction. This approach mirrors the current guidelines approach but is recalibrated.

The sensitivity analysis shows that recalibrating the absolute risk reduction by CHA$_2$DS$_2$-VASc score in the AFI database does not meaningfully change the primary conclusion. In fact, the sensitivity analysis showed that recalibration resulted in greater differences in estimates when compared to the Competing Risk Model.

8.2 Comparison of stroke/systemic embolism rates and absolute risk reduction with anticoagulants per 100 person-years re-estimated in the AFI database

CHA2DS2-VASc score*	Guidelines reported expected event rates (used in main analysis)		Event Rates from AFI	
	Ischemic Stroke/systemic embolism rate, off-treatment (Friberg 2012)**	Absolute Risk Reduction (Frieberg 2012 & Hart 2007)	Ischemic Stroke/systemic embolism rate recalibrated in AFI data, off-treatment (95% CI)	Absolute risk reduction re-estimated in AFI data
0	0.2	0.13	0.44 (0.07 to 1.46)	0.27
1	0.6	0.38	1.48 (0.97 to 2.16)	0.90
2	2.5	1.60	3.40 (2.67 to 4.27)	2.08
3	3.7	2.37	4.43 (3.66 to 5.36)	2.70
4	5.5	3.52	6.12 (5.08 to 7.34)	3.73
5	8.4	5.38	9.30 (7.52 to 11.53)	5.67
6	11.4	7.30	10.9 (8.1 to 14.6)	6.63
7	13.1	8.38	12.8 (6.2 to 23.5)	7.79
8	12.6	8.06	23.2 (7.4 to 56.0)	14.16

Legend

*no patients in the AFI database had a CHA_2DS_2-VASc score of 9

** Friberg 2012 did not present 95% confidence intervals, or the data needed to calculate confidence intervals

8.3 Table Estimated ARR by CHA_2DS_2-VASc model compared with Competing Risk Model and recalibrated CHA_2DS_2-VASc (replication of Figure 1)

Years after randomization	ARR by Competing Risk Model (Main analysis Fig 1)	ARR by CHA2DS2-VASc (Main analysis Fig 1)	ARR by recalibrated CHA2DS2-VASc (Sensitivity analysis)
1	2.4% [IQR 1.8% to 3.6%]	2.3% [IQR 1.6% to 3.5%]	2.7% [IQR 2.1% to 3.7%]
2	4.0% [IQR 2.9% to 5.8%]	4.6% [IQR 3.1% to 6.8%]	5.3% [IQR 4.1% to 7.2%]
3	5.2% [IQR 3.8% to 7.4%]	6.9% [IQR 4.7% to 10.0%]	7.8% [IQR 6.0% to 10.6%]
4	6.2% [IQR 4.5% to 8.7%]	9.0% [IQR 6.2% to 13.1%]	10.2% [IQR 8.0% to 13.9%]
5	6.3% [IQR 4.6% to 8.9%]	11.2% [IQR 7.7% to 16.1%]	12.6% [IQR 9.9% to 17.0%]

Appendix 9: Estimated ARR by CHA$_2$DS$_2$-VASc model compared to Competing Risk Model

9.1 Figure 1 in tabular format

Time horizon (years)	CHA$_2$DS$_2$-VASc model ARR, median (IQR)	Competing Risk Model ARR, median (IRQ)
1	2.3% (IQR 1.6%, 3.5%)	2.4% (IQR 1.8%, 3.6%)
2	4.6% (IQR 3.1%, 6.8%)	4.0% (IQR 2.9%, 5.8%)
3	6.9% (IQR 4.7%, 10.0%)	5.2% (IQR 3.8%, 7.4%)
4	9.0% (IQR 6.2%, 13.1%)	6.2% (IQR 4.5%, 8.7%)
5	11.2% (IQR 7.7%, 16.1%)	6.3% (IQR 4.6%, 8.9%)

9.2 Estimated cumulative incidence of stroke or systemic embolism by model and treatment status

Appendix 10: Misestimation of ARR by CHA$_2$DS$_2$-VASc score at 3 years (Figure 2 in tabular format)

Decile of life expectancy (range)	Absolute misestimation of CHA$_2$DS$_2$-VASc estimate at 3 years, mean (95% CI)	Relative misestimation of CHA$_2$DS$_2$-VASc estimate at 3 years (95% CI)
1 (16 to 47 yrs.)	-1.3% (-1.3% to -1.2%)	-44% (-46% to -41%)
2 (13 to 16 yrs.)	-1.0% (-1.1% to -0.9%)	-27% (-30% to -25%)
3 (11 to 13 yrs.)	-0.3% (-0.5% to -0.1%)	-7% (-10% to -4%)
4 (9 to 11 yrs.)	0.1% (-0.1% to 0.3%)	5% (2% to 8%)
5 (8 to 9 yrs.)	0.3% (0.1% to 0.5%)	9% (6% to 12%)
6 (7 to 8 yrs.)	0.5% (0.2% to 0.7%)	17% (15% to 20%)
7 (6 to 7 yrs.)	0.8% (0.6% to 1.0%)	23% (20% to 25%)
8 (5 to 6 yrs.)	1.8% (1.5% to 2.0%)	37% (34% to 41%)
9 (4 to 5 yrs.)	3.0% (2.7% to 3.2%)	58% (54% to 62%)
10 (1 to 4 yrs.)	4.7% (4.5% to 5.0%)	78% (74% to 82%)